Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31048244 | 1.00 | HSD17B10 (0.51) | HSD17B10SMN1; SMN2NPC1POLBKMT2A | |
| SCHEMBL25428390 | 0.98 | HSD17B10 (0.52) | HSD17B10SMN1; SMN2NPC1POLBKMT2A | |
| SCHEMBL10031609 | 0.94 | HSD17B10 (0.57) | HSD17B10SMN1; SMN2NPC1POLBKMT2A | |
| SCHEMBL903389 | 0.94 | HSD17B10 (0.57) | HSD17B10SMN1; SMN2NPC1POLBKMT2A | |
| SCHEMBL15317017 | 0.85 | HSD17B10 (0.51) | HSD17B10SMN1; SMN2NPC1KMT2AMEN1 | |
| SCHEMBL2307400 | 0.85 | HSD17B10 (0.51) | HSD17B10SMN1; SMN2NPC1KMT2AMEN1 | |
| SCHEMBL30987668 | 0.85 | HSD17B10 (0.51) | HSD17B10SMN1; SMN2NPC1KMT2AMEN1 | |
| SCHEMBL18787687 | 0.84 | HSD17B10 (0.50) | HSD17B10SMN1; SMN2NPC1POLBKMT2A | |
| SCHEMBL18787688 | 0.84 | HSD17B10 (0.50) | HSD17B10SMN1; SMN2NPC1POLBKMT2A | |
| SCHEMBL18358031 | 0.83 | HSD17B10 (0.62) | HSD17B10SMN1; SMN2NPC1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222326-A1 | New Heterocyclic Derivatives Useful For The Treatment of CNS Disorders | UCB PHARMA, S.A. (BE) | 2010-09-02 | — | — | US | disclosed |
| EP-2152262-A2 | NEW HETEROCYCLIC DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | UCB Pharma, S.A. (BE) | 2010-02-17 | — | — | EP | disclosed |
| WO-2008132142-A2 | NEW HETEROCYCLIC DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | UCB PHARMA S.A. (BE) | 2008-11-06 | — | — | WO | disclosed |
| WO-2008132139-A2 | NEW HETEROCYCLIC DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | UCB PHARMA S.A. (BE) | 2008-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222326-A1 | New Heterocyclic Derivatives Useful For The Treatment of CNS Disorders | CNR2, CNR1, SLC18A2 | HSD17B10 1091/4885SMN1; SMN2 144/4885NPC1 192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.